The HIV prevention field is facing a pivotal moment. Lenacapavir (LEN) for PrEP — the injection that offers near perfect protection against HIV — is rolling out at record speeds. Widely considered a breakthrough HIV prevention option, the early successes of injectable LEN's scale up are, in no small part, thanks to the coordinated efforts of advocates and civil society groups to push for accelerated processes.
LEN was launched in Eswatini and Zambia in December 2025 — just five months after the drug received US FDA approval — and as of May 2026 has rolled out in eight African countries. As implementation continues and more countries receive supplies, countries and communities need ongoing support to ensure LEN is delivered with speed, scale and equity, alongside other available PrEP options, to those who need it most.
It's against this backdrop that we are excited to introduce Access Bridge.
Incubated over the past decade at AVAC as part of their Product Introduction and Access team, Access Bridge is an independent, Kenya-based nonprofit organization advancing timely, sustainable and equitable introduction of and access to HIV prevention, sexual reproductive health and related health products.
Led by Executive Director Wawira Nyagah, who led AVAC's work in this area for over five years, and with a team of product introduction experts, Access Bridge brings a track record of proven success in moving HIV prevention options from evidence to real-world impact.